Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List

Stock News

2025/12/08

Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as "Jinpei Growth Hormone Injection") and the co-introduced Meishiya (commonly known as "Megestrol Acetate Oral Suspension").

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1153111707"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153111707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153111707?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153111707","market":"nz","top_or_hot":-1,"title":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List","media":"Stock News","content":"<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-08 16:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0075","symbol_name":"新三板","start_time":0,"source_url":"","article_id":"1153111707","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153111707","pubTimestamp":1765184295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0075":"新三板","BK0188":"融资融券","000661":"长春高新","BK0046":"生物疫苗","BK0057":"长吉图板块","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"长春高新技术产业（集团）有限责任公司。（000661.SZ）子公司有两种药品新纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}